Neurotech International Limited (ASX:NTI)

Market Cap	17.13M -55.6%
Revenue (ttm)	7.07M +8,687.8%
Net Income	-3.85M
EPS	-0.00
Shares Out	1.32B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,074,662
Average Volume	1,501,561
Open	0.0130
Previous Close	0.0130
Day's Range	0.0120 - 0.0130
52-Week Range	0.0100 - 0.0300
Beta	0.02
RSI	51.96
Earnings Date	Apr 27, 2026

About Neurotech International

Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxation in autistic children exhibiting elevated delta band brain activity. It also engages in executing medical research projects; and developing technolog...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NTI

Financial Performance

In fiscal year 2025, Neurotech International's revenue was 2.44 million, a decrease of -23.07% compared to the previous year's 3.18 million. Losses were -10.60 million, 109.1% more than in 2024.